Resultats globals: 2 registres trobats en 0.01 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
13 p, 861.9 KB Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial / Dimopoulos, M.A. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens. School of Medicine) ; Špička, I. (First Department of Medicine. Department of Hematology. First Faculty of Medicine. Charles University. General Hospital in Prague) ; Quach, H. (Department of Hematology. University of Melbourne. St Vincent's Hospital) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ; Garg, M. (Hematology. Leicester Royal Infirmary. University Hospitals of Leicester NHS Trust) ; Beksac, M. (Department of Hematology. Ankara University) ; Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ; Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ; Chng, W.J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ; Leleu, X. (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ; Mateos, M.V. (Hematology. Hospital Universitario de Salamanca. University Hospital of Salamanca. Centro de Investigación del Cáncer. Instituto de Biología Molecular y Celular del Cáncer. Universitario de Salamanca Consejo Superior de Investigaciones Científicas) ; Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ; Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ; Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ; Universitat Autònoma de Barcelona
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. [...]
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041  
2.
10 p, 667.7 KB Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX / Kaufman, J.L. (Winship Cancer Institute. Emory University) ; Dimopoulos, M (The National and Kapodistrian University of Athens) ; White, D. (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ; Benboubker, L. (Service d'Hématologie et Thérapie Cellulaire. Hôpital Bretonneau. Centre Hospitalier Régional Universitaire) ; Cook, G. (St James's Institute of Oncology. Leeds Teaching Hospitals National Health Service Trust and University of Leeds) ; Leiba, M. (Assuta Ashdod University Hospital. Faculty of Health Science Ben-Gurion University of the Negev) ; Morton, J. (Icon Cancer Care) ; Joy Ho, P. (Institute of Haematology. Royal Prince Alfred Hospital) ; Kim, K. (Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ; Takezako, N. (Department of Hematology. National Hospital Organization Disaster Medical Center of Japan) ; Moreau, P. (Hematology. University Hospital Hôtel-Dieu) ; Sutherland, H.J. (Leukemia/Bone Marrow Transplant Program. University of British Columbia) ; Magen, H. (Department of Hematology Chaim Sheba Medical Center. Ramat-Gan. Sackler Faculty of Medicine. Tel Aviv University) ; Iida, S. (Department of Hematology and Oncology. Nagoya City University Graduate School of Medical Sciences) ; Kim, J.S. (Yonsei University College of Medicine. Severance Hospital) ; Miles Prince, H. (Cabrini Hospital. Epworth HealthCare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Cochrane, T. (Gold Coast University Hospital and Griffiths University) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bahlis, N.J. (University of Calgary. Arnie Charbonneau Cancer Institute) ; Chari, A. (Icahn School of Medicine at Mount Sinai) ; O'Rourke, L. (Janssen Research & Development) ; Trivedi, S. (Janssen Research & Development) ; Casneuf, T. (Janssen Research & Development) ; Krevvata, M. (Janssen Research & Development) ; Ukropec, J. (Janssen Global Medical Affairs) ; Kobos, R. (Janssen Research & Development) ; Avet-Loiseau, H. (Unite de Genomique du Myelome. IUC-Oncopole) ; Usmani, S.Z. (Levine Cancer Institute/Atrium Health) ; San-Miguel, J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Universitat Autònoma de Barcelona
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. [...]
2020 - 10.1038/s41408-020-00375-2
Blood Cancer Journal, Vol. 10 Núm. 11 (january 2020) , p. 111  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.